Table 4.

Difference in expected hct values for a median-aged black malea receiving a fixed dose of epoetin alfa at a facility in the lowest versus highest quintile of centers grouped by aggregate hematocrit in the 2000 and across strata for incidence versus prevalence, and dialysis adequacy defined by URR

Epo DoseTime on HemodialysisURRDifference in Expected Hct between Facilities (Actual Data; Mean [95% CI])Difference in Expected Hct between Facilities (Simulated Data; Mean [95% CI])
25% quintile (low dose)Incident<603.3 (3.2 to 3.4)0.1 (−0.2 to 0.3)
≥752.9 (2.8 to 3.0)0.0 (−0.2 to 0.1)
Prevalent<603.0 (2.9 to 3.1)0.1 (−0.1 to 0.2)
≥752.7 (2.6 to 2.8)−0.1 (−0.2 to 0.0)
Median (middle dose)Incident<603.4 (3.2 to 3.5)0.1 (−0.1 to 0.2)
≥753.0 (2.9 to 3.1)−0.1 (−0.2 to 0.0)
Prevalent<603.1 (3.0 to 3.2)0.0 (−0.1 to 0.1)
≥752.7 (2.7 to 2.8)b−0.1 (−0.2 to 0.0)
75% quintile (high dose)Incident<603.5 (3.4 to 3.6)0.0 (−0.1 to 0.2)
≥753.1 (3.0 to 3.2)−0.1 (−0.2 to 0.0)
Prevalent<603.2 (3.1 to 3.3)0.0 (−0.2 to 0.1)
≥752.8 (2.8 to 2.9)b−0.2 (−0.1 to 0.0)
  • a With diabetes, disabled, using iron therapy, and other continuous variables set at median for population, including Charlson Comorbidity Index, number of days in the hospital, health access, socioeconomic, poverty, urbanization, number of stations per center, number of patients per center, total patients per station, number of hct measures per patient, and for-profit facility type.

  • b CI boundaries are rounded to the first decimal.